Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
AADSMAmerican Academy of Dental Sleep Medicine
AASMAmerican Academy of Sleep Medicine
ABPMAmbulatory blood pressure monitoring
ACPAmerican College of Physicians
ACSAcute coronary syndrome
ADHDAttention-deficit/hyperactivity disorder
AEAdverse event
AFAtrial fibrillation
AHFSAmerican Hospital Formulary Service
AHIApnea-hypopnea index
AHI3aApnea-hypopnea index based on hypopneas with at least 3% desaturation or arousal
AHI4Apnea-hypopnea index based on hypopneas with at least 4% oxygen desaturation
AHIAltApnea-hypopnea index, AASM alternative hypopnea definition (at least 50% airflow reduction and at least 3% desaturation or arousal)
AHIChicagoApnea-hypopnea index, Chicago criteria hypopnea definition
AHIRecApnea-hypopnea index, AASM recommended hypopnea definition (at least 30% airflow reduction and at least 4% desaturation)
AJRCCMAmerican Journal of Respiratory and Critical Care Medicine
APAAsset purchase and license agreement
APAPAuto-adjusting positive airway pressure (auto-PAP)
APIActive pharmaceutical ingredient; application programming interface (in a ClinicalTrials.gov record label)
ATO-OXYAtomoxetine-oxybutynin
Ato75Atomoxetine 75 mg
ATSAmerican Thoracic Society
AUCArea under the plasma concentration-time curve
AUCinfArea under the plasma concentration-time curve extrapolated to infinity
AUClastArea under the plasma concentration-time curve to the last measurable concentration
BIDTwice daily
BMIBody mass index
BPBlood pressure
BPAPBilevel positive airway pressure
CADCoronary artery disease
CEConformité Européenne
CENTRALCochrane Central Register of Controlled Trials
CHIPChildren's Health Insurance Program
CIConfidence interval
CLConfidence limit
CmaxMaximum plasma concentration
CMCChemistry, manufacturing, and controls
CMOsContract manufacturing organizations
CMSCenters for Medicare & Medicaid Services
CNSCentral nervous system
COMISAComorbid insomnia and obstructive sleep apnea
COVID-19Coronavirus disease 2019
CPAPContinuous positive airway pressure
CPGClinical practice guideline
CrClCreatinine clearance
CROContract research organization
CSSACocaine Selective Severity Assessment
CVCardiovascular
CVDCardiovascular disease
CYPCytochrome P450
CYP1A2Cytochrome P450 1A2
CYP2C9Cytochrome P450 2C9
CYP2D6Cytochrome P450 2D6
CYP3ACytochrome P450 3A
CYP3A4Cytochrome P450 3A4
D&EDiet and exercise
DALYDisability-adjusted life year
DMCData monitoring committee
DMEDurable medical equipment
DOADuration of approval
DORAsDual orexin receptor antagonists
DSM-5Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
DSSTDigit Symbol Substitution Test
ECGElectrocardiogram
EDSExcessive daytime sleepiness
EEGElectroencephalography
EMGElectromyography
EOGElectrooculography
EOSEnd of study
EREmergency room; extended release
ERSEuropean Respiratory Society
ESExcessive sleepiness
ESKDEnd-stage kidney disease
ESSEpworth Sleepiness Scale
FAQsFrequently asked questions
FASFull Analysis Set
FDAU.S. Food and Drug Administration
FOSQFunctional Outcomes of Sleep Questionnaire
GIRKG-protein-coupled inwardly rectifying potassium
GLP-1Glucagon-like peptide-1
GLP-1 RAGlucagon-like peptide-1 receptor agonist
GMRGeometric mean ratio
HBHypoxic burden (based on 4% desaturation)
HB4Hypoxic burden based on 4% desaturation
HbA1cGlycated hemoglobin (hemoglobin A1c)
HCUHealth care utilization
HGNSHypoglossal nerve stimulation
HIHepatic insufficiency
HMNHypoglossal motor nucleus
HNSHypoglossal nerve stimulation
HRHazard ratio
HRQoLHealth-related quality of life
HSATHome sleep apnea testing
HSTHome sleep test
ICERIncremental cost-effectiveness ratio
ICSD-3International Classification of Sleep Disorders, Third Edition
ICSD-3-TRInternational Classification of Sleep Disorders, Third Edition, Text Revision
IDIdentifier
IMPInvestigational medicinal product
INBIncremental net benefit
INBpPooled incremental net benefit
INDInvestigational new drug application
IPDIndividual participant data
IPTWInverse probability of treatment weighting
IQRInterquartile range
ISAACCImpact of Sleep Apnea Syndrome in the Evolution of Acute Coronary Syndrome
ITTIntent-to-treat
LG1Loop gain
LOCFLast observation carried forward
LSLeast squares
MACCEMajor adverse cardiac or cerebrovascular events
MACEMajor adverse cardiovascular events
MACRAMedicare Access and CHIP Reauthorization Act of 2015
MADMandibular advancement device
MAOIMonoamine oxidase inhibitor
MCIMild cognitive impairment
MDMean difference
MIMyocardial infarction
MIPAMembership Interest and Asset Purchase Agreement
MIPSMerit-based Incentive Payment System
mITTModified intention-to-treat
MMOMaxillo-mandibular osteotomy
MMRMMixed model for repeated measurements
MNARMissing not at random
MrOSOsteoporotic Fractures in Men Study
MTDMaximum tolerated dose
MVCMotor vehicle collision
N1Non-rapid eye movement sleep stage 1
N2Non-rapid eye movement sleep stage 2
N3Non-rapid eye movement sleep stage 3
NCTNational Clinical Trial (ClinicalTrials.gov identifier)
NDANew Drug Application
NHANESNational Health and Nutrition Examination Survey
NHATSNational Health and Aging Trends Study
NREMNon-rapid eye movement
NRINorepinephrine reuptake inhibitor
NSFNational Sleep Foundation
NYSENew York Stock Exchange
OAOral appliance
OAHIObstructive apnea-hypopnea index
ODIOxygen desaturation index
ODI3Oxygen desaturation index based on 3% desaturation
ODI4Oxygen desaturation index based on 4% desaturation
OLEOpen-label extension
OROdds ratio
OSAObstructive sleep apnea
OTCOver-the-counter
PAPPositive airway pressure
PATPeripheral arterial tonometry
PBOPlacebo
PDUFAPrescription Drug User Fee Act
PFASPrimary Full Analysis Set
PGI-CPatient Global Impression of Change
PGI-SPatient Global Impression of Severity
PKPharmacokinetics
PLMPeriodic limb movement
PPS-APer Protocol Set for AHI4
PQRSPhysician Quality Reporting System
PROPatient-reported outcome
PROMISPatient-Reported Outcomes Measurement Information System
PROMIS-FPROMIS Fatigue
PROMIS-SIPROMIS Sleep Impairment
PROMsPatient-reported outcome measures
PRSAPhysician-reported sleep apnea
PSGPolysomnography
PVTPsychomotor Vigilance Test
QALYQuality-adjusted life year
QDOnce daily
QoLQuality of life
QQQuantity and Quality of Work scale
QTcQT interval corrected for heart rate
RCTRandomized controlled trial
RDIRespiratory disturbance index
REIRespiratory event index
REI4Respiratory event index with hypopneas defined by 4% oxygen desaturation
REMRapid eye movement
REMLRestricted maximum likelihood
RERAsRespiratory effort-related arousals
RICCADSARandomized Intervention With CPAP in Coronary Artery Disease and Sleep Apnea
RRRelative risk
SAESerious adverse event
SaO2Arterial oxygen saturation
SAPStatistical analysis plan
SAQLISleep Apnea Quality of Life Index
SASSleep apnea syndrome
SASSShionogi-Apnimed Sleep Science, LLC
SAVESleep Apnea Cardiovascular Endpoints
SDStandard deviation
SDBSleep-disordered breathing
SEStandard error
SF-3636-Item Short Form Health Survey
SF-6DShort Form 6-Dimension
SHHSSleep Heart Health Study
SMUsSingle motor units
SNRIsSelective norepinephrine reuptake inhibitors
SpO2Oxygen saturation (pulse oximetry)
SRSystematic review
SSSafety Set
STARStimulation Therapy for Apnea Reduction
STOPSnoring, Tiredness, Observed apnea, and high blood Pressure (screening questionnaire)
SWDShift work disorder
T2DType 2 diabetes
T90Time spent during sleep with oxygen saturation below 90%
TBTTennis ball technique
TCAsTricyclic antidepressants
TETreatment emergent
TEAETreatment-emergent adverse event
TFTask Force
TmaxTime to maximum plasma concentration
TSTTotal sleep time
UCUsual care
UIUncertainty interval
UKUnited Kingdom
USUnited States
USAUnited States of America
V2Visit 2
V3Visit 3 (randomization visit)
V4Visit 4
VA/DoDU.S. Department of Veterans Affairs and Department of Defense
VBAVisual Basic for Applications
VOLTVisual Object Learning Task
WASOWake after sleep onset
WHOWorld Health Organization